DATA GRAPHICS | Data Byte
CHMP’s November opinions include four new medicines and an expansion of Mounjaro’s label to include obesity
By Gunjan Ohri, Data Content Analyst
November 11, 2023 12:35 AM UTC
After a re-examination of the data, EMA’s CHMP has changed its thinking on Mirati’s KRAS inhibitor, recommending approval. The decision was one of four positive opinions the committee issued for new therapies at its November meeting. Also among the highlights was a recommendation to expand the label of Lilly’s Mounjaro to include obesity.
In July, CHMP had issued a negative opinion on Krazati adagrasib from Mirati Therapeutics Inc. (NASDAQ:MRTX) noting that the data were not comprehensive and failed to show whether the KRAS inhibitor fulfills an unmet need. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650623/after-a-second-look-ema-s-chmp-recommends-mirati-s-kras-inhibitor